Absolute risk
The probability of an event or outcome occurring in a defined population over a specified time period
Absolute risk reduction
A measure of treatment effect that compares the decrease in risk in the control group with that of a treatment group i.e. Pc – Pt
Adverse event
An undesirable effect of a health technology
Avatrombopag (Doptelet®). HTA ID: 20006
Avatrombopag is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure.
| NCPE Assessment Process | Complete |
| Rapid review commissioned | 11/02/2020 |
| Rapid review completed | 02/04/2020 |
| Rapid Review outcome | A full HTA is not recommended. The NCPE recommends that avatrombopag be considered for reimbursement*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.
The HSE has approved reimbursement; September 2020